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Overload of neonatal and adult cardiomyocytes and mul­ticellular myocardial preparations, which include whole 
hearts, are accompanied by an enhanced activity of the 
Na+/H+ exchanger 1 (NHE-1). Exogenous administration of 
prohypertrophic agents such as angiotensin II (Ang II), 
endothelin-1 (ET-1), and cq-adrenergic agonists also stimu­
lates NHE-1 activity, which leads to an increased concentra­
tion of intracellular Na+ (| Na |,). Moreover, inhibition of 
NHE-1 activity prevents the increase in |Na |,. induces the 
regression of cardiac hypertrophy, and exerts beneficial 
effects in experimental heart failure.
The present review summarizes the current knowledge of 
the causative factors and pathophysiological correlation of 
cardiac overload and NHE-1 activity.
The Na+/H+ Exchanger
NHE is an integral membrane glycoprotein expressed ubiq­
uitously in mammalian cells, and it electroneutrally ex­
changes intracellular H+ for extracellular Na+ (1:1) to regu­
late intracellular pH (pl I,) and the concentration of | Na |,. 
Nine isoforms of this exchanger have been described: NHE-1 
to NHE-9. NHE-1, the first isoform to be cloned, is expressed 
ubiquitously in the plasma membrane and is considered to be 
the cardiac-specific isoform.1 The inward gradient of Na+, 
produced mainly by the Na+/K+ ATPase, provides a constant 
driving force for H+ extrusion and Na+ influx through the 
NHE.
NHE-1 (Figure 1) is a protein of 815 amino acid residues 
with a predicted molecular mass of 85 kDa that can be 
separated into an N-terminal membrane-associated domain 
('--500 amino acid residues) and a long C-terminal cytoplas­
mic tail. The membrane domain, composed of 12 transmem­
brane regions, is associated with ionic transport, and it 
contains the allosteric H+ sensor site that determines the 
exquisite sensitivity of the exchanger to intracellular H+. The 
cytoplasmic domain ('--300 amino acid residues) is involved 
in the regulation of the activity of the exchanger by several 
mechanisms. Removal of the distal region of the cytosolic tail 
causes a shift of the pl I sensitivity to the acidic side and an 
important inhibition of NHE-1 activation by growth factors.1
NHE-1 is constitutively phosphorylated, and further phos­
phorylation increases its activity. The phosphorylation sites 
are targets of extracellular signal-regulated kinases 1 and 2 
(ERK1/2), p90rek, and other protein kinases such as Rho 
kinase and Nck-interacting kinase.1-2 It has been demon­
strated that Ca2+/calmodulin (CaM)-dependent kinase II 
(CaMKII) can phosphorylate the C-terminal domain of the 
NHE-1 in vitro. Some other protein kinases such as protein 
kinase C (PKC) and protein kinase D are able to influence 
NHE-1 activity in response to neurohormonal stimulation, 
although they are not believed to phosphorylate the ex­
changer directly. NHE-1 is susceptible to dephosphorylation 
by protein phosphatases I and 2A.3-4 Other mechanisms of 
regulation of NHE-1 activity involve phosphorylation and/or 
dephosphorylation of regulatory proteins or interaction with 
cofactors. The binding proteins CaM, calcineurin B homolo­
gous protein 1, and tescalcin exert an inhibitory effect on the 
exchanger activity that is released when they bind Ca2+. 
Overexpression of calcineurin B homologous protein 1 pre­
vents the activation of NHE-1, and this effect is abolished by 
growth factor stimulation. Cells transfected with tescalcin 
exhibit a marked inhibition of NHE-1 activity after an acid 
load. The cytosolic tail, in its region proximal to the mem­
brane domain, also includes 2 putative inositol 4,5- 
biphosphate binding sites involved in ATP regulation of 
NHE-1. Although the exchanger does not use ATP directly, 
ATP depletion decreases transport activity significantly.1-2
Another enzyme that has recently been reported to influ­
ence NHE-1 activity is carbonic anhydrase II.5 Carbonic 
anhydrase II catalyzes the hydration of CO2 to HCO, and H . 
The enzyme binds to the cytosolic domain, and the binding is 
a function of NHE-1 phosphorylation.5 Inhibition of carbonic 
anhydrase II decreases NHE-1 activity.5
The actin-binding proteins of the ezrin, radixin, and moesin 
family form important links between the cytoskeleton and 
integral proteins of the plasma membrane, and they interact 
with the cytosolic tail of NHE-1.2 Therefore, NHE-1 func­
tions as a scaffold for recruitment of signaling complexes.
Enhanced Function of the NHE-1: |Na+ [ or pHj?
Stimulation of heptahelical receptors coupled to Gaq protein 
by Ang II, ET, and cq-adrenergic agonists, as well as reactive 
oxygen species (ROS) and intracellular acidosis, are well- 
known activators of the NHE-1, at least in part, through
Received March 15. 2006; accepted August 30. 2006.
From the Centro de Investigaciones Cardiovasculares. Facultad de Ciencias Médicas. Universidad Nacional de La Plata. La Plata. Argentina.
Correspondence to Dr Horacio E. Cingolani. Centro de Investigaciones Cardiovasculares. Facultad de Ciencias Médicas. LTniversidad Nacional de La
Plata. Calle 60 y 120, 1900 La Plata. Argentina. E-mail ciernes ©infovia.com.ar
(Circulation. 2007;115:1090-1100.)
© 2007 American Heart Association. Inc.
Circulation is available at http://vvvvvv.circulationaha.org DOI: 10.1161/CIRCULATIONAHA.106.626929
1090
Cingolani and Ennis The Na+/H+ Exchanger in Myocardial Hypertrophy 1091
D
ow
nloaded from http: ahajonnials.org by on A
ugust 23. 2019
Figure 1. Ang II and ETs, as well as other guanine nucleotide- 
binding protein a-q couple receptor agonists, activate PKC and 
the NHE-1 and Na -independent CI7HCO3‘ exchanger (AE). 
Moreover, neither Ang II nor ET stimulation of NHE-1 induces 
intracellular alkalization when bicarbonate is present in the 
medium because of the simultaneous activation of AE through a 
PKC-dependent phosphorylation.7-108 The increased H extru­
sion by NHE-1 activity is therefore offset by the H+ equivalent 
influx through the AE. On the contrary, because of the Na - 
independence of AE, the influx of Na+ through NHE-1 is not off­
set by the AE, and therefore its intracellular concentration 
increases. Several sites of interaction with factors potentially 
involved in the regulation of the exchanger activity in the cyto­
solic tail of NHE-1 have been described. PIP2 indicates inositol 
4,5-biphosphate; CHP-I, calcineurin homologous protein I; ERM, 
ezrin, radixin, and moesin actin binding family of proteins; CaM, 
calmodulin; TES, tescalcin; and CAII, carbonic anhydrase II.
mitogen-activated protein kinase (MAPK) activation.6 Other 
autocrine, paracrine, and hormonal factors, such as epidermal 
growth factor, aldosterone, adenosine, thrombin, and osmo­
larity also modulate the exchanger activity.6 Although NHE-1 
hyperactivity is often thought to be associated with an 
increase in pHb this is not necessarily correct. In the presence 
of bicarbonate, stimulation of NHE-1 by Ang II or ET-1 does 
not induce intracellular alkalosis, because a bicarbonate- 
dependent acidifying mechanism, the Cl/HCO, exchanger, is 
activated simultaneously through a PKC-dependent mecha­
nism.7 We would like to emphasize this point because the 
absence of changes in pl I in bicarbonate media after growth 
factor stimulation is not yet widely recognized, although it 
was reported by Ganz et al8 in 1988 in mesangial cells and 
there was a call for attention to this fact in a letter to Nature 
by Thomas a year later (Figures 1 and 2).9
NHE-1 Inhibition as a Potential 
Therapeutic Strategy
Strong evidence exists that the harmful effect of NHE-1 
hyperactivity is the result of the increase in [Na+]j that leads 
to Ca2+ overload through the Na+/Ca2+ exchanger (NCX), 
myocardial dysfunction, hypertrophy, apoptosis, and fail-
Figure 2. A representation of the proposed autocrine/paracrine 
cascade of events that follow myocardial stretch. Endogenous 
Ang II is released from the myocytes, which activates AT! 
receptors in an autocrine fashion. Stimulation of AT| induces the 
release/formation of ET, which simultaneously activates NHE-1 
and AE through the ETA receptors. Activation of the AE prevents 
the expected intracellular alkalization caused by activation of 
NHE-1 but does not prevent the rise in [Na+]i- The increase in 
[Na+]j drives NCX in the reverse mode, and this, together with a 
probable direct action on the exchanger, leads to the increase 
in Ca2+ transient. Abbreviations as in Figure 1.
ure.10-14 Consequently, inhibition of its hyperactivity 
emerges as a therapeutic strategy to prevent the deleterious 
consequences of increases in [Na+]j and intracellular Ca2+ 
concentration ([Ca2+]i), activation of many intracellular path­
ways, and their effects: ischemia/reperfusion injury, hyper­
trophy, necrosis, and apoptosis.
The pharmacological evidence that supports the beneficial 
effect of NHE-1 inhibition in ischemia/reperfusion injury was 
confirmed in mice hearts with genetic ablation of NHE-1 
(NHE-l-null mutant, Nhe I ) that exhibited enhanced resis­
tance to ischemic and reperfusion injury.15 Furthermore, a 
recent report showed that NHE-1 hyperactivity can be 
blunted by a decrease in its phosphorylation level at serine 
703 on the C terminus by generation of dominant negative- 
p90 ribosomal S6 kinase transgenic (DN-RSK-TG) mice, 
which showed reduced cardiomyocyte apoptosis and ische­
mia/reperfusion injury after 45 minutes of left coronary 
occlusion.16
NHE-1 Inhibitors
Several NHE-1 inhibitors were developed with the goal of 
cardioprotection after exchanger activation by prevention of 
[Na+]i and [Ca2+]i accumulation. Amiloride, a sparing K 
diuretic, was the first compound proposed to inhibit the 
exchanger. NHE-1 and NHE-2 are the isoforms most sensi­
tive to this drug, which also inhibits Na+ channels and NCX. 
Amiloride derivatives were synthesized to improve the po­
tency and selectivity of the NHE-1 isoform. Double substi­
tution of the nitrogen atom of the 5-amino group yielded 
several compounds, of which ethylisopropil amilorode was 
one of the most frequently used. Its IC50 was »400 times less 
than that of amiloride and with less action on Na+ channels 
and NCX. Further investigations led to benzoylguanidines 
such as HOE-694, HOE-642 (cariporide), EMD96785 (eni- 
poride), BIIB-513, BIIB 723, EMD 87580, and other chem­
ically related compounds such as SM-20550 and zoniporide
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(CP-597396). The IC50 of most of the newly developed 
compounds is of the same order of magnitude as that of 
ethylisopropil amilorode, but with much higher selectivity for 
the NHE-1. These compounds differ in their solubility, the 
possible routes of administration, and persistence of the effect 
after drug washout.17
Clinical Perspectives
In broad terms, NHE-1 inhibition appears to be a new 
pharmacological tool for the treatment of ischemia/reperfu- 
sion injury, myocardial infarction, apoptosis, heart failure, 
pathological cardiac hypertrophy, and remodeling. Evidence 
also exists that NHE inhibition provides benefits after cere­
brovascular ischemia by prevention of activation of phospho­
lipases during reperfusion.17 As described for the heart and 
brain, renal ischemia enhances the activity of the NHE, 
especially the NHE-3 isoform, and its inhibition has benefi­
cial effects.17 Unfortunately, the promising results obtained in 
experimental animal protocols of ischemia/reperfusion injury 
could not be reproduced in clinical trials. In 2 large clinical trials 
(Guard During Ischemia Against Necrosis [GUARDIAN] and 
Evaluation of the Safety and Cardioprotective Effects of Enipo- 
ride in Acute Myocardial Infarction [ESCAMI]), no overall 
clinical benefit was detected after NHE-1 inhibition in acute 
coronary syndromes.1819 A cardioprotective effect was detected 
after eniporide only in a smaller trial ( 100 patients) in individuals 
with acute myocardial infarction who underwent percutaneous 
transluminal coronary angioplasty.20 The most recent study, the 
Sodium-Hydrogen Exchange Inhibition to Prevent Coronary 
Events in Acute Cardiac Conditions (EXPEDITION) Study, 
revealed myocardial benefits of cariporide treatment in patients 
with ischemic heart disease, but unfortunately and unexpectedly 
the treatment was associated with significantly greater incidence 
of strokes.1 Whether these pharmacological adverse effects are 
common to all NHE-1 inhibitors or are peculiar to cariporide is 
not apparent to us at present. The possibility of a deleterious 
effect of NHE-1 inhibition under basal conditions in contrast to 
a beneficial effect, when inhibition occurs only after an acid 
load, has been proposed recently.416 Therefore, although at first 
glance this new therapeutic strategy may appear difficult to 
practice, it deserves further study.
Cardiac Overload and NHE-1
We will focus especially on the concentric hypertrophy 
characterized by an increase in the thickness of the ventric­
ular wall caused by parallel addition of sarcomeres with 
re-expression of a fetal gene program and little or no chamber 
dilatation. This cardiac phenotype can be triggered by sys­
temic hypertension, aortic stenosis, and myocardial infarc­
tion. Concentric left ventricular hypertrophy is the predomi­
nant form of cardiac hypertrophy, and it very frequently 
precedes cardiac dilation and failure. We will exclude from 
this review a discussion of the mechanisms involved in 
physiological cardiac hypertrophy. The relationship of 
NHE-1 activation to this interesting hypertrophic pathway, 
which involves the PI3K/Akt/GSK-3/3 and mammalian target 
of rapamycin-dependent pro-growth factors, has not been 
explored. It would be interesting to explore the level of 
activation of the NHE-1 and the effect of its inhibition on 
hypertrophy in Akt-1 knockout mice, in which ET-1 induces 
exaggerated cardiac hypertrophy, but the cardiac growth 
response to exercise is blunted.21 Pathological cardiac hyper­
trophy can be the result of multiple intracellular signaling 
pathways triggered through the stimulation of membrane 
receptors by neurohumoral factors and/or by myocardial 
stretch. The mechanical stress imposed by the increase in wall 
tension is the primary event sensed in the transduction of the 
mechanical load. Integrins and the associated cytoskeletal 
proteins interact with the extracellular matrix, and possibly 
they sense mechanical stress and trigger intracellular prohy- 
pertrophic signaling pathways. Integrins are well-known 
mechanotransducers that have been shown to increase their 
expression in both physiological and pathological cardiac 
hypertrophy.22 These proteins form the costameres, the junc­
tional complex localized at the Z lines that connect the 
sarcomeres to members of the Z disc proteins, such as 
a-actin, vinculin, talin, and melusin, and to the extracellular 
matrix. Interestingly, this zone is rich in NHE-1 and NCX 
units. However, the link between the costameres and the 
activity of the exchangers deserves future research.
In an attempt to mimic cardiac overload under controlled 
conditions, isolated neonatal and adult rat cardiac myo­
cytes, 2118 multicellular preparations such as papillary mus­
cles from different species. ”4'' 17 and even whole rat and pig 
hearts181 have been stretched to induce mechanical defor­
mation and activation of the intracellular prohypertrophic 
signaling pathways. Considering all these results together, 
and despite some discrepancies about the intracellular cas­
cade activated by myocardial stretch, the findings can be 
summarized by the scheme presented in Figure 2. Myocardial 
stretch induces the release of preformed Ang II that, through 
AT! receptor stimulation, induces the release/formation of 
ET, which binds to ETA receptors and activates NHE-1, 
possibly by phosphorylation of serine 703 by the ERK1/2- 
p90rsk pathway.52 The exchanger activation is followed by an 
augmentation of [Na+]j that modifies the thermodynamic 
conditions for the NCX that leads to an increase in [Ca2+]j 
caused by a decrease in Ca2+ efflux (forward mode of 
operation of the NCX) and/or an increase in Ca2+ influx 
(reverse mode). Increased production of ROS as a result of 
Ang II/ET stimulation of nicotinamide adenine dinucleotide 
phosphate oxidase may be one of the pathways involved in 
the activation of ERK l/2-p90lk.5i51 However, ROS may be 
involved in several other steps of the intracellular signaling 
pathway triggered by myocardial stretch as depicted in Figure 
2 3i.54.55 Tp^ initial step of this cascade, the release of Ang II, 
was proposed first by Sadoshima et al25 in isolated neonatal 
rat ventricular myocytes. In fact, this group of researchers 
found that the culture medium of the stretched cardiac 
myocytes (conditioned medium) caused induction of 
immediate-early genes and activation of prohypertrophic 
signaling pathways in nonstretched myocytes.56 In line with 
these results is the work by van Wamel et al,32 which showed 
that the conditioned medium from stretched myocytes con­
tained Ang II and ET-1, which are involved in the cardio­
myocyte hypertrophic response. Moreover, Ito et al57 found in 
neonatal rat cardiomyocytes that Ang II promoted the release/ 
formation of ET-1, and that the hypertrophic effect of Ang II
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Figure 3. The stretch of a papillary mus­
cle produces a rapid initial increase in 
force (A, a and b), caused by an increase 
in myofilament Ca2 responsiveness. 
Immediately after and during the next 10 
to 15 minutes, a progressive increase in 
force develops: the SFR (A, b and c) that 
is caused by an increase in Ca2+ tran­
sients (B). AT| and ETA blockers blunt 
both the SFR and the increase in Ca2 
transients (C and D). Modified from 
Alvarez et al,40 with permission of the 
publisher. Copyright © 1999, the Ameri­
can Heart Association.
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was blocked by an ETA receptor antagonist or by the 
introduction of an antisense sequence against the coding 
region of preproET-1 mRNA, which demonstrated that ET-1 
was an autocrine/paracrine factor in the mechanism of Ang 
Il-induced cardiac hypertrophy. Yamazaki et al28 reported 
that stretch promoted an increase of the constitutively se­
creted ET-1 into the culture medium together with an increase 
in MAPKs and NHE-1 activities in neonatal rat cardiomyo­
cytes. Interestingly, in this study NHE-1 inhibition partially 
inhibited activation of MAPKs. Therefore, in isolated neona­
tal cardiac myocytes, the results are in agreement with the 
cascade of events, starting with the release of Ang II and ET 
followed by activation of NHE-1, thus increasing [Na+]j and, 
by this mechanism promoting the rise in [Ca2+]j through the 
NCX. However, the results obtained from experiments per­
formed in neonatal cells can be problematic because these 
cells possess different relative receptor subtypes and cell­
signaling mechanisms, and the participation of NCX in the 
excitation-contraction coupling is much greater than in adult 
cells.1-58 Nevertheless, the experiments performed in isolated 
cardiomyocytes, multicellular preparations, and even whole 
hearts from adult animals that we discuss next are consistent 
with those of neonates and confirm the chain of events 
depicted in Figure 2.
The mechanical counterpart that follows the stretch of 
multicellular myocardial preparations, such as cat papillary 
muscles (Figure 3), represents a useful model to visualize the 
role played by the local renin-angiotensin-endothelin system 
in the chain of events depicted in Figure 2. When muscle 
length is increased, corresponding rapid and slow increases in 
developed force can be observed.14-59 The rapid change in 
force is thought to be the basis of the Frank-Starling mech­
anism and is induced by an increase in myofilament Ca2+ 
sensitivity. On the other hand, the slow force response (SFR) 
is caused by a progressive increase in the Ca2 transient 
amplitude without changes in myofilament responsiveness, a 
finding first reported by Allen and Kurihara in 198260 and 
later by several other laboratories (Figure 3).40-59-60 According 
to the proposed chain of events, the SFR is also abolished by 
inhibition of ET-converting enzyme by phosphoramidon,42 
NHE-1 blockade, and NCX reverse mode inhibition with 
KB-R79 43.42-43-47
The pivotal role of NHE-1 activation in this autocrine/ 
paracrine chain of events has been reported by several 
investigators.14-33-39-40-42_46 The role of ET as the activator of 
the NHE-1 after myocardial stretch has been confirmed by 
Calaghan and White41 in ferret papillary muscles but not by 
von Lewinsky et al44-45 in rabbit papillary muscle or in failing 
human myocardium. Despite confirming the activation of 
NHE-1, von Lewinsky et al were unable to detect the role of 
Ang II or ET in its activation. Differences between species in 
the extent of the stretch or in the ET isoform released by 
stretch may account for these discrepancies. In connection 
with this, the stretch of cat papillary muscles induced the 
upregulation of preproET-3 mRNA, whereas the stretch of 
pig and rat myocardium upregulated ET-1.36 Nevertheless, 
the 3 ET isoforms are equipotent in their ability to stimulate 
NHE-1 activity.46 The possible role of stretch-operated chan­
nels (SOC) in the myocardial response to mechanical stress is 
also controversial. Sadoshima et al24 and Yamazaki et al30 did 
not find participation of these channels in the hypertrophic 
response of neonatal rat cardiac myocytes to stretch. Von 
Lewinsky et al44-45 tested the possible role of SOC in the 
mechanical counterpart that follows myocardial stretch, the 
SFR, in nonfailing rabbit myocardium and in failing human 
myocardium. No effect of gadolinium or streptomycin, 2 
SOC inhibitors, was detected on the response to stretch.44-45 
However, Calaghan and White33 reported that the activation
1094 Circulation March 6, 2007
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of both SOC and NHE-1 underlie the SFR in isolated 
myocytes and in multicellular muscle preparations from adult 
rat heart. Isenberg et al61 proposed that myocardial stretch 
increases [Na+] and [Ca2+] in the cytosol and in cell or­
ganelles partly by their influx through the SOC, but they were 
unable to prevent the increase in [Na+]j by cariporide.
Ang II, ET-1, and aradrenergic agonists activate conven­
tional heterotrimeric G protein-dependent and unconven­
tional G protein-independent intracellular pathways. More­
over, recent evidence suggests that G protein coupled 
receptors can trigger intracellular signals independent of G 
protein activation.62 Ang II/ET and aradrenergic agonists by 
generation of anion superoxide activate the ERK 1/2^90”* 
pathway that phosphorylates and consequently activates the 
NHE-1 that triggers intracellular signaling pathways.52
In line with the concepts illustrated by Figures 2 and 3 are 
experiments that show that the SFR can be mimicked by 
small amounts of exogenous Ang II (1 nmol/L).63 The 
positive inotropic effect seen in a multicellular preparation 
such as cat papillary muscle, as well as in isolated cat 
ventricular myocytes, is abrogated completely by AT! or ETA 
receptors blockade, NHE-1-specific inhibition, or inhibition 
of the reverse mode of the NCX.40-42-43
In vivo studies in pig heart showed that the first molecular 
response to pressure overload was the disappearance of the 
granular staining that corresponded to Ang II stores in the 
cardiomyocyte cytoplasm after 30 minutes of the imposed 
overload.50 These findings were followed by an increase in 
the mRNA of preproET-1 and angiotensinogen, changes that 
were abrogated by AT! receptor blockade.50 Furthermore, in 
situ mRNA hybridization revealed that ventricular myocytes 
were the source of ET-1 in the hypertrophied hearts in vivo.64
Cardiomyocyte-specific disruption of the ET-1 gene in 
mice reduced the hypertrophic response to tri-iodothyronine, 
which suggests that myocyte-produced ET-1, which acts in a 
paracrine/autocrine manner, is an important signal for myo­
cardial hypertrophy development in response to thyroid 
hormone.65 Thus, converging pieces of evidence coming from 
experiments in neonatal rat ventricular myocytes, adult myo­
cytes, multicellular preparations, and whole hearts support 
the theory that the activation of NHE-1 is an early event after 
myocardial stretch triggered by the activation of the local 
renin-angiotensin-endothelin system and leads to an increase 
in [Ca2+]i through the NCX. This chain of events can be 
mimicked also by applying small amounts of any ET iso­
form. n-46-63 Furthermore, as we discuss in the next section of 
this review, the NHE-1 has been demonstrated to be activated 
in several models of cardiac hypertrophy, and its specific 
inhibition resulted in prevention/regression of hypertrophy.
The NHE-1 in Myocardial Hypertrophy
Enhanced activity of NHE-1 in the hypertrophied myocardi­
um of spontaneously hypertensive rats (SHR) was reported in 
1995.66 67 The hyperactivity of NHE-1 has been described for 
several other tissues from hypertensive humans and other 
animals.68 Experiments in our laboratory showed that the 
hyperactivity of NHE-1 in the hypertrophied myocardium of 
SHR was not accompanied by an increase in pHj because 
simultaneous activation of the acidifying CT/HCO3' ex­
changer occurred (Figure l).67 The increased activity of 
NHE-1 was, in this model, the result of a PKC-dependent 
posttranslational modification of the exchanger.69 It was 
further hypothesized that inhibition of the antiporter activity 
could regress and/or prevent the development of the hyper­
tensive hypertrophy. Camilion de Hurtado et al70 reported that 
the myocardial hypertrophy of SHR regressed with cariporide 
treatment with no change in arterial pressure. Another feature 
of the hypertensive cardiac hypertrophy is the enhancement 
of interstitial fibrosis, which was decreased by long-term 
blockade of NHE-1, although this effect took longer than the 
regression of myocyte size,71 possibly as a reflection of the 
lower turnover rate of collagen metabolism.72
The link between NHE-1 activity and myocardial growth 
has been established for several other neurohormonal models 
of cardiac hypertrophy in addition to hypertensive hypertro­
phy. Kusumoto et al73 showed that NHE-1 was upregulated 
after myocardial infarction and that the specific inhibition of 
this exchanger with cariporide decreased hypertrophy and 
remodeling in these hearts. Upregulation of NHE-1 was 
reported for the cardiac hypertrophy and failure model of the 
/3radrenergic receptor transgenic mice.74 In this model, 
NHE-1 inhibition prevented the development of cardiac 
hypertrophy and fibrosis, and NHE-1 inhibition normalized 
the expression of the exchanger, which suggests that its 
upregulation is essential for the detrimental cardiac effects of 
long-term ^¡-receptor stimulation in the heart.74 Similarly, the 
cardiac hypertrophy induced in rats by repeated isoproterenol 
administration was prevented by the inhibition of NHE-1.75 
The mechanism(s) by which /3-adrenergic receptor stimula­
tion induces upregulation at both the translational and post­
translational levels of NHE-1 in the myocardium is not clear.
Hypertrophied hyperthyroid hearts showed enhanced 
NHE-1 activity, and when exposed to acute ischemia they 
accumulate more Na+ than the control nonhypertrophied 
hearts; these changes were prevented by NHE-1 inhibition.10 
Moreover, it has been demonstrated that thyroid hormone, by 
the interaction of its receptor with the NHE-1 promoter, 
increases the expression of the NHE-1 protein.76
In patients with end-stage renal disease and secondary 
hyperparathyroidism, as well as in patients with primary 
hyperparathyroidism, a strong correlation between cardiac 
hypertrophy and serum parathyroid hormone levels has been 
reported.77-78 Although the observation is controversial,79-80 a 
stimulatory effect of parathyroid hormone over NHE-1 has 
been described; therefore, it is tempting to speculate about the 
possible involvement of the antiporter in the signaling path­
way evoked by parathyroid hormone in the genesis of cardiac 
hypertrophy.
In neonatal rat ventricular myocytes, aldosterone stimula­
tion induced a hypertrophic response accompanied by up­
regulation of NHE-1 at both the mRNA and protein levels 
accompanied by increased [Na+]i. Both hypertrophy and 
elevated [Na+]i were prevented by the NHE-1-specific inhib­
itor EMD87580 as well as the aldosterone antagonist spirono­
lactone.81 Similar results were obtained in uninephrectomized 
rats exposed to deoxycorticosterone acetate/salt, in which 
treatment with cariporide completely inhibited hypertrophy 
and NHE-1 upregulation.82
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Recently, a very interesting study reported that cardiac 
hypertrophy of atrial natriuretic peptide receptor-deficient 
mice was accompanied by an increased activity of NHE-1 
with increased [Ca2+]i.83 Long-term treatment with the 
NHE-1 inhibitor cariporide normalized these alterations.80 
These results are in line with a report by Tajima et al, who 
demonstrated that atrial natriuretic peptide inhibits NHE-1 
activity.84
Leptin, a protein encoded by the obesity gene, has been 
reported to activate NHE-1 through a PKC-dependent path­
way,85 and emerging evidence indicates that this hormone is 
linked to cardiac hypertrophy.8'’ 88 It has been reported that 
leptin elevates ET-1 and ROS levels, which results in hyper­
trophy of neonatal rat cardiac myocytes.87 Therefore, it seems 
reasonable to speculate that NHE-1 hyperactivity is involved 
in this prohypertrophic signaling pathway. More recently, 
Karmazyn’s group87 implicated leptin as an autocrine medi­
ator of the hypertrophic effects of Ang II and ET-1 in cultured 
neonatal ventricular myocytes.88 Whether leptin is upstream 
and/or downstream of ET-1 secretion appears to be contro­
versial.87-88 Myocardial NHE-1 mRNA abundance was en­
hanced in right ventricular hypertrophy caused by 
monocrotaline-induced pulmonary artery injury. Both hyper­
trophy and NHE-1 upregulation were abrogated by treatment 
with cariporide.89
In a preliminary report, carbonic anhydrase II inhibition 
was reported to reverse cardiac hypertrophy, an effect prob­
ably related to its stimulatory effect on NHE-1 as mentioned 
before.90 When the sarcolemmal NHE-1 activity from normal 
human donor hearts was compared with that of hearts with 
chronic end-stage heart failure that exhibited varying degrees 
of hypertrophy, a significantly greater NHE-1 activity was 
detected in the hypertrophied myocytes.91 This report, along 
with others, opens the possibility of considering the inhibition 
of NHE-1 as a new therapeutic strategy for cardiac failure. 
We should keep in mind that NHE-1 is one of the main 
pathways for Na+ entry into the cardiac cell.92
In the Table, we summarize the cardiac hypertrophy 
models in which NHE-1 activation may be involved. As we 
mentioned before, an enhanced activity of NHE-1 may be the 
result of an increased expression of the exchanger, an 
increased turnover of the functional units, or a combination of 
both alternatives. In line with this view, the models reviewed 
clearly exhibited cases of enhanced NHE-1 activity caused by 
upregulation of the exchanger expression, posttranslational 
modification, or a combination of both. In any case, the 
hyperactivity of NHE-1 was linked to cardiac hypertrophy. 
Interestingly, whereas long-term NHE-1 inhibition by caripo­
ride in the whole animal induces upregulation of the exchang­
er,103 the normalization of its previously augmented expres­
sion has also been reported after long-term NHE-1 
inhibition.74-75-83-89 Several aspects require further investiga­
tion to clarify the precise mechanism by which NHE-1 is 
involved in the development of cardiac hypertrophy and 
failure and its possible link with other intracellular signaling 
pathways. A disparate negative result about the antihypertro- 
phic effect of NHE-1 inhibition in rats was reported by 
Loennechen et al,1144 who described a salutary effect of
Models of Cardiac Hypertrophy in Which NHE-1 Plays a Role
Cardiac Hypertrophy Model References
Cardiac overload 12, 63, 64, 67, 93
Stretch of rat neonatal cardiac myocytes 25, 27
Ang II stimulation 27, 49
ET-1 stimulation 25, 27, 54, 94
Postmyocardial infarction 70, 95-97
Leptin stimulation 82-85
Human heart failure 89
Monocrotaline-induced 86
Hyperparathyroidism 77, 98
Hyperthyroidism 170
Hamster model hereditary cardiomyopathy 13
Mineralocorticoid stimulation 78, 79
Atrial natriuretic peptide receptor-deficient mice 80
Carbonic anhydrase inhibition 5, 88
/3-Adrenergic stimulation 71, 72, 99
«-Adrenergic stimulation 94, 100, 101
Pacing-induced 102
losartan on postinfarction remodeling and gene expression 
that was not shared by cariporide.1144
Probable Mechanisms by Which NHE-1 
Inhibition Induces an Antihypertrophic Effect 
The multiple hypertrophic signals appear to converge on a 
common set of nuclear transcription factors that will interact 
to activate or repress transcription of certain cardiac genes. 
Research into the effect of NHE-1 inhibition on the activity of 
these transcription factors is lacking. Because modifications 
of [Na+]i secondary to NHE-1 activity are believed to be 
followed by changes in [Ca2+]j, it seems reasonable to assume 
that the changes in [Ca2+]j (diastolic, systolic, or restricted to 
certain intracellular spaces) will be a downstream step from 
NHE-1 inhibition in its antihypertrophic effect. However, the 
possibility that NHE-1 inhibition decreases ROS formation 
makes the interpretation of the mechanism more complicated 
because it is possible that >1 hypertrophic pathway is 
targeted by NHE-1 blockade. NHE-1 inhibition in adult SHR 
during 1 month was followed by regression of cardiac 
hypertrophy with normalization of calcineurin A/3 expression 
and nuclear abundance of nuclear factor of activated T 
cells.105 If we consider the results reported by Kilic et al, the 
calcineurin/nuclear factor of activated T cells pathway is 
probably not the only pathway involved in myocardial hy­
pertrophy triggered by pressure overload.83 Kilic et al re­
ported an increased activity of NHE-1, augmented [Ca2+]i, 
and activation of the 4 prohypertrophic signaling pathways 
examined: the MAPKs, the serine-threonine kinase Akt, 
calcineurin, and CaMKII. However, the regression of cardiac 
hypertrophy induced by the treatment with cariporide nor­
malized only 2 of these signaling pathways, the CaMKII and 
the Akt.
Changes in pHj
After the report that fertilization of sea urchin eggs was 
followed by a rise in pl I,. it has became widely accepted that
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action potential
Ctrl Ctrl-car HF HF-car
’ 500 ms '
calcium transient
Figure 4. When rabbits with cardiac hypertrophy and failure 
(caused by combined pressure and volume overload) were 
treated repeatedly with the NHE-1 inhibitor cariporide for 3 
months, prevention of cardiac hypertrophy and normalization of 
the previously high diastolic levels of Ca2+ were observed. This 
figure shows representative examples of action potential (top) 
and calcium transients (bottom) in myocytes of the control 
group (Ctrl), control treated with cariporide group (Ctrl-car), the 
heart failure group (HF), and the heart failure treated with cari­
poride (HF-car) groups. Reproduced from Baartscheer et al12 
with permission of the publisher. Copyright © 2005, the Euro­
pean Society of Cardiology.
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intracellular alkalization caused by enhanced NHE-1 activity 
was responsible for the increase in protein synthesis and cell 
growth.106 107 Therefore, if this notion is correct, the inhibi­
tion of NHE-1 would reverse and prevent cardiac hypertro­
phy by normalization of pl I,. However, in SHR hypertrophy 
the enhanced activity of NHE-1 is not accompanied by 
intracellular alkalosis, as we have already mentioned.67 Fur­
thermore, in a medium that contains bicarbonate, Ang II and 
ET-1 do not increase pHi.14-39-40-42-43-65-108 Therefore, keeping 
in mind this observation, we should expect that NHE-1 
inhibition will not change pHj significantly when 
bicarbonate-dependent mechanisms are operative. In agree­
ment with this, a recent publication demonstrates that long­
term treatment with cariporide, without significantly altering 
pH,, induces the regression of cardiac hypertrophy, preven­
tion of heart failure, and normalization of elevated [Na+]j and 
[Ca2+]j (Figure 4).12 We should therefore be cautious as we 
extrapolate the absence of pHj changes in spite of NHE-1 
activation to conditions other than myocardial stretch and 
Ang II/ET stimulation.83
Changes in [Na+]j
An increase in [Na+]j is detected after NHE-1 stimulation by 
Ang II, ET-1, or myocardial stretch. Although the magnitude 
of the increase in | Na | reported by different authors and for 
different species is somewhat variable, it ranges from 3 to 
6 mmol/L.12-40-47 It is known that the increase in | Na ] can 
induce an increase in [Ca2+]j through the NCX as a result of 
a decrease in Ca2+ efflux (decreased forward mode) and/or an 
increase in Ca2+ entry (increased reverse mode). The increase 
in [Na+]j induced by stretch and by exogenous Ang II or 
ET-1, at doses that produce similar increases in force to the 
SFR, is prevented by blocking NHE-1.11-40-42-65 This increase 
in [Na+]j shifts the reversal potential of the NCX (ENCX) to a 
more negative potential to give more time for the NCX to 
operate in reverse mode during the action potential and 
promotes Ca2+ influx to the cell, which determines the 
increase in force. As reported by Bers et al,97 cardiomyocytes 
have a limited capacity to buffer increases in |Na |,. and 
NCX is more sensitive than the Na+/K+ ATPase pump to a 
change in [Na+]j of this magnitude.
Recently, Baartscheer et al12 showed that long-term treat­
ment with cariporide of rabbits with combined pressure and 
volume overload cardiac hypertrophy and failure attenuated 
hypertrophy and decreased the previously augmented diastol­
ic [Ca2+]j without significant alteration of systolic [Ca2+]j. 
Recent experiments performed in isolated neonatal rat ven­
tricular myocytes by Dulce et al94 showed that the hypertro­
phic response to ET-1 was accompanied by increases in 
[Na+]b [Ca2+]b cell surface area, phenylalanine incorporation, 
and atrial natriuretic peptide mRNA expression. These effects 
were diminished by the blockade of NHE-1 with cariporide 
and by the inhibition of the reverse mode of NCX with 
KB-R7943.94 Experiments performed by Karmazyn’s group 
showed that the decrease in Na+ influx caused by the NHE-1 
inhibitor EMD87580 attenuates and reverses myocardial 
hypertrophy and heart failure after myocardial infarction.109 
Similar results were reported by Chahine et al,13 who used the 
hereditary cardiomyopathic hamster model of cardiac hyper­
trophy and failure. In this case, the blockade of NHE-1 by 
EMD87580 prevented the development of hypertrophy and 
necrosis by preventing the increase in Na+ influx through the 
NHE-1.13
Changes in [Na+]j may trigger intracellular signals inde­
pendently of altering the reverse potential of the NCX.11 It 
has been reported that an increase in [Na+]j can stimulate 
PKC activity110 and perhaps it may stimulate production of 
ROS.111 Furthermore, additional factors of the NHE-l-medi- 
ated increase in [Na+]j exist that need to be considered in the 
autocrine/paracrine loop triggered by myocardial stretch that 
may contribute to the rise in [Ca2+]j: the increase in action 
potential duration112 and the increased ROS production that 
targets the NCX.113 Both effects are probably caused by Ang 
II/ET-1 stimulation of nicotinamide adenine dinucleotide 
phosphate oxidase and anion superoxide formation.
Experiments performed in NCX knockout mice challenged 
the possible role of this exchanger in the determination of 
cardiac hypertrophy development.96 Further experiments are 
necessary to rule out the possibility that NCX knockout mice 
develop adaptive compensatory mechanisms responsible for 
the hypertrophic response.
Mitochondrial Effects and ROS
Emerging evidence indicates that NHE-1 can be activated by 
ROS. This pathway of activation involves ERK1/2- and 
p90rsk-dependent phosphorylation.52114 In connection with 
this, the positive inotropic effect of 1 nM Ang II assessed by 
sarcomere shortening is blunted by the scavenger N-(2- 
mercapto-propionyl) glycine in isolated myocytes.55 Less
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well explored is the possibility that the increased ROS 
production, in addition to its role upstream in the cascade of 
activation of NHE-1, may be induced by the rise in |Na | 
secondary to NHE-1 hyperactivity. In connection with this, 
and as was mentioned before, the results of the experiments 
reported by Yamazaki et al28 showed that myocyte stretch 
induced NHE-1 and MAPK activation, and that specific 
blockade of NHE-1 partially decreases the activation of 
MAPK. Furthermore, Javadov et al115 showed recently in rats 
with myocardial infarction that NHE-1 inhibition was able to 
prevent cardiac hypertrophy completely and decrease the 
vulnerability of mitochondria to Ca2+. NHE-1 inhibition also 
increased mitochondrial respiratory function, especially at the 
level of complex I and complex II. lavadov and colleagues 
attributed the antihypertrophic effect of NHE-1 inhibition to 
the decreased generation of mitochondrial-derived 
ROS.115116
As to the putative relationship between NHE-1 activity and 
oxidative stress and the possibility that ROS has a role 
downstream from in addition to upstream of the exchanger 
activation, we should remember that the granulocyte super­
oxide production induced by Ang II has been reported to be 
reduced under NHE-1 inhibition,117 and that Ang Il-induced 
increased cardiac production of ROS in in vivo experiments 
is abrogated by a low-Na-l- diet.111 Moreover, the decrease in 
infarct size and level of tissue lipoperoxidation (assessed by 
thiobarbituric acid reactive substances), induced by ROS 
scavengers administered during the reperfusion, can be mim­
icked by specific blockade of NHE-1.118
It seems possible that ROS may participate in several steps 
of the intracellular prohypertrophic pathway triggered by 
myocardial stretch. A recent study reports that ROS can 
mediate the upregulation of NHE-1 gene expression and thus 
increase cell resistance to death.119
Mitochondrial NHE can be blocked by several NHE 
blockers, which include cariporide1-0~122; therefore, these 
drugs block both NHE-1 (sarcolemmal) and mitochondrial 
NHE.
In a recent study, the effect of cariporide on cell death 
induced by oxidative stress was examined in cultured neona­
tal cardiomyocytes.123 Despite the fact that the NHE-1 inhib­
itor suppressed the cytosolic Na+ and Ca2+ accumulation 
nearly completely and prevented the loss of mitochondrial 
membrane potential induced by H2O2, the beneficial effect on 
the apoptosis markers evaluated was only partial, which 
suggests a contribution of Ca2+-independent death pathways, 
such as cytochrome c release. Furthermore, an action of 
cariporide that delays mitochondrial matrix acidification and 
preserves ATP levels has been suggested.120
Karmazyn’s group also reported that the opening of the 
mKATP channels by diazoxide blunted the a-adrenergic- 
induced hypertrophy and NHE-1 upregulation in neonatal rat 
cardiomyocytes.101 Because a decrease in the amount of 
mitochondrial ROS release by opening the mKATP channels 
has been described,124 a relationship between mKATP, ROS, 
NHE-1 and cardiac hypertrophy seems probable. Therefore, 
NHE-1 inhibition may exert its beneficial effects by decreas­
ing [Na+]j and/or ROS production. Both [Na+]i and ROS 
target the NCX to modify its activity, and therefore target 
|(’a2 | either in the bulk of the cytosol or in more restricted 
spaces.
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